The study will compare FWY003 with placebo in people with this eye condition. It is a randomized study, which means the treatment is assigned by chance, and double masked, which means neither the participants nor the study team know who receives FWY003 or placebo during the study. Over time, the study follows changes in the damaged area in the eye and also watches for side effects and other health changes. The study lasts for many months and includes regular visits during which eye health and general well-being are reviewed.

Participants in the study will receive either ADX-038 or a placebo through a subcutaneous injection, which is a method of delivering medication into the fatty tissue just beneath the skin. The study will monitor changes in the size of the affected areas and the health of the photoreceptors, which are the specialized cells in the eye that respond to light. This process involves using advanced imaging techniques such as optical coherence tomography, a non-invasive way to take cross-section pictures of the retina, and fundus autofluorescence, a specialized eye imaging test that helps visualize the health of the retinal layers.

The study will test a new medication called ONL1204, which is given as an injection directly into the eye (intravitreal injection). Some participants will receive ONL1204, while others will receive a sham injection. The purpose is to determine if ONL1204 can slow down the progression of Geographic Atrophy in people with AMD.

During the study, participants will receive multiple eye injections over a period of 60 days. The total amount of medication given will not exceed 1200 micrograms. Throughout the study, doctors will monitor changes in the areas of retinal damage to assess how well the treatment is working.

Participants in the study will be randomly assigned to receive either the GAL-101 eye drops or a matching placebo, which looks like the GAL-101 solution but does not contain the active ingredient. The study is designed to be “double-masked,” meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will take place over a period of time, during which participants will use the eye drops and have regular check-ups to monitor their eye health and the size of the affected area in the retina.

The main goal of the study is to evaluate how effective GAL-101 is in reducing the rate of change in the size of the damaged area in the retina. Participants will undergo various eye examinations, including a method called fundus autofluorescence (FAF), which helps visualize the retina, and optical coherence tomography (OCT), which provides detailed images of the retina. These tests will help researchers understand how the treatment affects the progression of the disease. The study aims to provide valuable information on the safety and effectiveness of GAL-101 for people with non-foveal geographic atrophy due to age-related macular degeneration.

The purpose of the study is to evaluate how these treatments affect the growth of lesions, or damaged areas, in the eye over a period of 52 weeks. Participants will receive either Pozelimab in combination with Cemdisiran, Cemdisiran alone, or a placebo. The study will involve regular visits to the clinic for injections and monitoring of eye health. Participants will undergo various tests to assess changes in their vision and the size of the lesions in their eyes.

This trial aims to provide valuable information on the safety and effectiveness of these treatments for individuals with Geographic Atrophy due to Age-Related Macular Degeneration. The study will help determine if these medications can slow down the progression of the disease and improve or maintain vision in affected individuals.

The purpose of the study is to evaluate how effective and safe ANX007 is in improving visual function and clarity in patients with GA. Participants in the study will receive either the ANX007 injection or a placebo. The study will last for 24 months, during which participants will have monthly visits to monitor their progress and any side effects. The main goal is to see if ANX007 can help maintain or improve vision over time.

Throughout the study, researchers will closely observe any changes in vision and any potential side effects. The study will also track the overall safety of the treatment to ensure it is well-tolerated by participants. This research aims to provide valuable insights into the potential benefits of ANX007 for people living with GA due to AMD.

The purpose of this study is to evaluate the long-term safety and effectiveness of Pegcetacoplan in individuals with Geographic Atrophy due to AMD. Participants in this study will receive regular injections of Pegcetacoplan over a period of time. The study will monitor the safety of the treatment and its impact on the progression of the disease. Participants will undergo various assessments to track changes in their vision and the condition of their eyes.

This study is an extension of previous research, meaning it continues to follow participants who have already been involved in earlier trials of Pegcetacoplan. The goal is to gather more information about how the treatment works over a longer period and to ensure it remains safe for use. Participants will be closely monitored by healthcare professionals throughout the study to ensure their well-being and to collect valuable data on the treatment’s effects.

Participants in the trial will receive daily injections of either Elamipretide or a placebo, which looks like the treatment but does not contain the active ingredient. The study will monitor changes in the eye over time, specifically looking at the area of the eye affected by the disease. This will help determine if Elamipretide can slow down or improve the condition.

The trial will last for a period of time, with regular check-ups to assess the health of the participants’ eyes. The study aims to provide valuable information on whether Elamipretide can be a beneficial treatment option for those suffering from Dry Age-Related Macular Degeneration.

Participants in this study will have previously been involved in earlier studies where they received either the JNJ-81201887 treatment or a sham treatment, which is a procedure that mimics the treatment but does not contain the active substance. The study will monitor participants over time to observe any side effects or changes in their condition. This will include regular eye examinations and imaging tests to check the health of the retina, which is the part of the eye affected by Geographic Atrophy.

In addition to JNJ-81201887, the study will also involve the use of Prednisone, a medication that is commonly used to reduce inflammation. Participants may receive Prednisone in tablet form or a placebo that looks like the Prednisone tablets but does not contain the active ingredient. The study aims to gather comprehensive data on the safety of these treatments and their effects on the participants’ vision and overall health.

The purpose of the study is to explore the safety and effectiveness of Tinlarebant in treating Geographic Atrophy. Participants in the study will be randomly assigned to receive either the Tinlarebant tablet or the placebo. The study will last for 24 months, during which participants will have regular check-ups and eye examinations to monitor the size of the affected areas in the retina and assess any changes in vision.

Throughout the study, various tests will be conducted to ensure the safety of the participants and to gather information on how the treatment affects the disease. These tests will include eye exams, blood tests, and other assessments to monitor overall health and any potential side effects. The study aims to provide valuable insights into the potential benefits of Tinlarebant for individuals with Geographic Atrophy.

The purpose of this study is to monitor the safety of GT005 over an extended period. The treatment involves a special type of injection called a suspension for injection, which is administered under the retina. This study will observe participants for up to five years to check for any side effects or health issues that might arise from the treatment.

Participants in this study have previously been treated with GT005 in earlier studies named FOCUS, EXPLORE, and HORIZON. The study will focus on identifying any adverse events, which are unexpected health problems that might occur during the study period. This long-term follow-up is essential to ensure the continued safety of the treatment for those with geographic atrophy due to age-related macular degeneration.

The purpose of this study is to find the right dose of Danicopan that can help patients with GA. Participants in the study will receive either Danicopan or a placebo, which looks like the real medication but does not contain the active substance. The study will last for a period of time, during which participants will take the medication and have regular check-ups to monitor their condition and any changes in their vision.

Throughout the study, researchers will assess how Danicopan affects the size of the GA lesions in the eye, as well as other aspects of eye health and vision. The study will also track any side effects or adverse events that participants may experience. This research aims to provide valuable information about the potential benefits and risks of using Danicopan for treating GA in patients with AMD.

Participants in the study will receive either the JNJ-81201887 treatment or a sham procedure. The study will monitor changes in the size of the affected areas in the eye over time. This will help researchers understand if the treatment is effective in slowing down the progression of Geographic Atrophy. The study will take place over a period of time, and participants will have regular check-ups to assess their eye health and the effects of the treatment.

In addition to the main treatment, some participants may receive other medications such as Prednisone, which is a type of steroid that can help reduce inflammation. Another medication that might be used is Kenacort-A, which contains Triamcinolone Acetonide, another type of steroid. These medications are given in tablet form or as a suspension for injection, depending on the specific needs of the study. The study aims to provide valuable information on the potential benefits of JNJ-81201887 for people with Geographic Atrophy due to Age-related Macular Degeneration.

During the course of the study, participants will receive monthly injections of avacincaptad pegol for a period of up to 17 months. Some participants may receive a placebo instead. The study will monitor participants for any adverse effects, which are unwanted or harmful reactions to the treatment. Additionally, the study will evaluate the body’s immune response to the medication, known as immunogenicity, and how the drug is processed in the body, referred to as pharmacokinetics.

This study is an open-label extension, meaning that both the researchers and participants know which treatment is being administered. It is designed for patients who have completed the previous study and aims to provide further insights into the safety of avacincaptad pegol for treating geographic atrophy. The study is expected to conclude in April 2025.